181 related articles for article (PubMed ID: 17178842)
1. Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy.
Iga AM; Sarkar S; Sales KM; Winslet MC; Seifalian AM
Cancer Res; 2006 Dec; 66(24):11517-9. PubMed ID: 17178842
[TBL] [Abstract][Full Text] [Related]
2. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.
Siemann DW
Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444
[TBL] [Abstract][Full Text] [Related]
3. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
4. Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation.
Vajkoczy P; Ullrich A; Menger MD
Neoplasia; 2000; 2(1-2):53-61. PubMed ID: 10933068
[TBL] [Abstract][Full Text] [Related]
5. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
6. Vascular disrupting agents (VDAs) in anticancer therapy.
Daenen LG; Roodhart JM; Shaked Y; Voest EE
Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
[TBL] [Abstract][Full Text] [Related]
7. Vascular-disrupting agents in oncology.
Mita MM; Sargsyan L; Mita AC; Spear M
Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
[TBL] [Abstract][Full Text] [Related]
8. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
9. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
10. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz JL
Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
[TBL] [Abstract][Full Text] [Related]
13. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
14. ASA404: update on drug development.
Rehman F; Rustin G
Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
[TBL] [Abstract][Full Text] [Related]
15. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
16. Chapter 9. Intravital videomicroscopy in angiogenesis research.
MacDonald IC; Chambers AF
Methods Enzymol; 2008; 444():201-30. PubMed ID: 19007666
[TBL] [Abstract][Full Text] [Related]
17. Vascular targeting tumor therapy: non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation.
Eichhorn ME; Klotz LV; Luedemann S; Strieth S; Kleespies A; Preissler G; Lindner M; Jauch KW; Reiser MF; Clevert DA
Cancer Biol Ther; 2010 May; 9(10):794-802. PubMed ID: 20234173
[TBL] [Abstract][Full Text] [Related]
18. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
Spear MA; LoRusso P; Mita A; Mita M
Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190
[TBL] [Abstract][Full Text] [Related]
19. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
Wu XY; Ma W; Gurung K; Guo CH
J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
